Skip to content

Value of Uric Acid as Early Predictor of Lupus Nephritis

Value of Uric Acid as Early Predictor of Lupus Nephritis in Assiut University Hospital

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05402735
Enrollment
100
Registered
2022-06-02
Start date
2022-06-15
Completion date
2023-08-25
Last updated
2022-06-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Uric Acid

Brief summary

The aim of the present work is to determine the role of uric acid as a predictor and prognostic factor in the development of lupus nephritis.

Detailed description

Systemic Lupus Erythematosus (SLE) is a systemic autoimmune disorder identified by the production of autoantibodies and immune complex deposition \[1\]. It presents with a variety of unpredictable flares of disease activity and irreversible organ damage \[2\]. Half or more (45%-85%) of patients with SLE will develop Lupus Nephritis (LN) over the course of their lifetime, which is a major concern \[3,4\]. Despite advanced immunosuppressive therapy, the 5-year survival rate of SLE patients with severe renal damage (11%-33%) is usually very low \[5\]. Hence, early prediction and diagnosis of LN are of great value. So far, renal biopsy remains to be the gold standard tool for diagnosis of LN \[6\] and assumes a vital role in its management and prognosis. However, renal biopsy can have various complications including hemorrhage and infection. Besides, some patients have contraindications for renal biopsy, which indicates the requirement for noninvasive markers for evaluating renal dysfunction and its grade \[7\]. \- Elimination of serum uric acid (SUA), the circulating endproduct of purine metabolism, occurs via both renal and extrarenal (gastrointestinal tract) pathways \[8\]. Kang and colleagues \[9\] have reported that elevated serum uric acid may also be a risk factor for progression of renal disease, in spite of the fact that it is considered as one of the markers of renal dysfunction. Elevated serum uric acid itself can lead to kidney damage without the deposition of uric acid crystals as reported in different studies \[10\]. Other studies strongly suggest to consider the concept of asymptomaticity for chronic hyperuricemia and hence to check the normal level of serum uric acid levels \[11\]. Hyperuricemia can be observed in patients with diabetic nephropathy , IgA nephropathy , metabolic syndrome and cardiovascular diseases \[12,13,14,15\]. In addition, a noteworthy positive relationship was detected between serum level of uric acid and new onset lupus nephritis. Elevated sUA has been observed as an independent risk factor for the development of LN . The correlation between sUA and the degree of renal dysfunction in LN patients was previously analyzed but in a few studies as in Calich and colleagues study who reported an association between lupus nephritis and high serum UA . Therefore the aim of the current study was to evaluate serum uric acid level and detect if hyperuricemia can independently predict and affect prognosis of LN among SLE patients.

Interventions

DIAGNOSTIC_TESTSerum uric acid level

Serum uric acid level

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years

Inclusion criteria

* All patients fulfilled the European League Against Rheumatism (EULAR) and the American college of rheumatology (ACR)

Exclusion criteria

*

Design outcomes

Primary

MeasureTime frameDescription
Value of uric acid as early predictor of lupus nephritis in Assiut University hospital1 yearThe aim of the present work is to determine the role of uric acid as a predictor and prognostic factor in the development of lupus nephritis. The aim of the present work is to determine the role of uric acid as a predictor and prognostic factor in the development of lupus nephritis.

Countries

Egypt

Contacts

Primary ContactEman gamal neyaz
geman3171@gmail.com01060893042
Backup ContactSalwa Salah Eldeen Elgendi salah
salwaelgendi@yahoo.com01005766155

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026